The Use of Biomarkers in Prostate Cancer Screening and Treatment.

Ashley VA1, Joseph MB2, Kamlesh KY3, Shalini SY3, Ashutosh KT3, Joseph R2.

Author information

Abstract

Prostate cancer screening and diagnosis has been guided by prostate-specific antigen levels for the past 25 years, but with the most recent US Preventive Services Task Force screening recommendations, as well as concerns regarding overdiagnosis and overtreatment, a new wave of prostate cancer biomarkers has recently emerged. These assays allow the testing of urine, serum, or prostate tissue for molecular signs of prostate cancer, and provide information regarding both diagnosis and prognosis. In this review, we discuss 12 commercially available biomarker assays approved for the diagnosis and treatment of prostate cancer. The results of clinical validation studies and clinical decision-making studies are presented. This information is designed to assist urologists in making clinical decisions with respect to ordering and interpreting these tests for different patients. There are numerous fluid and biopsy-based genomic tests available for prostate cancer patients that provide the physician and patient with different information about risk of future disease and treatment outcomes. It is important that providers be able to recommend the appropriate test for each individual patient; this decision is based on tissue availability and prognostic information desired. Future studies will continue to emphasize the important role of genomic biomarkers in making individualized treatment decisions for prostate cancer patients.

KEYWORDS:

4Kscore; Apifiny; Biomarkers; ConfirmMDx; Decipher; Michigan Prostate Score; PCA3; PTEN/TMPRSS2:ERG; ProMark; Prolaris; Prostate Health Index; Prostate cancer; SelectMDx